Why the study?
Do different subclasses of 1,4 dihydropyridine calcium antagonists have different effects on cardiac outcomes in patients with hypertension and CAD?
Do different subclasses of 1,4 dihydropyridine calcium antagonists have different effects on cardiac outcomes in patients with hypertension and CAD?
Answers are grounded in this paper and cite their sources.
This review highlights that while 1,4 dihydropyridine calcium antagonists are used for hypertension and CAD, some subclasses may have detrimental cardiac outcomes.
The 1,4 dihydropyridine calcium antagonists have several properties that theoretically make them attractive for treatment of hypertension and prevention as well as management of coronary artery disease (CAD). However, some of them appear to have actions that are detrimental for outcome. This brief review will first address the different subclasses of dihydropyridines, then outline differences between these subclasses which may impact on outcome in CAD and hypertension, and the last part will review present evidence for differences in cardiac outcome.
No takes yet. Share an insight, caveat, or question.
Frans H. H. Leenen (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: